Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Health

Genetics

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Parkinson's

More Like This

Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156

PR Newswire associated0

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Bial Launches Education and Awareness Campaign for World Parkinson’s Day

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Exidavnemab phase 2a study expanded to include MSA patients

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile